
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a promising biotechnology company with a strong focus on developing transformative therapeutics for retinal diseases using its proprietary ABC platform. The company has a diversified pipeline with three late-stage clinical programs, including tarcocimab and KSI-501, which are being explored for retinal vascular diseases with topline data readouts expected in 2026 and 2027. With its innovative approach and high-potential products, Kodiak Sciences has a positive outlook and an appealing price target of $61, supported by its strong clinical data, successful trial results, and expected revenue growth.
Bears say
Kodiak Sciences is a biopharmaceutical company that has developed a new technology platform for retinal medicines, but based on financial and intellectual property risks, as well as competition from other big biopharma companies, their investigational medicines may not reach peak commercial revenue and could face delays or failures in gaining approval or reimbursement. This could lead to suboptimal commercialization and increased cash burn, which may negatively impact Kodiak's prospects and future growth potential.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares